Perform a pilot study in an immunodeficient mouse model
Not delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 16 Feb 2021
- Due
- 30 Jun 2021
- Checked
- 25 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“A pilot study in an immunodeficient mouse model is planned to be performed in the second quarter of 2021”
What we found
Evidence strength A What the grades mean
The company delayed the start of the NC-iMSC pilot study to the third quarter of 2021, missing the original second-quarter deadline.
-
A Citius Pharmaceuticals, Inc. 8-K filed 2021-07-07
“Q3 2021 • Dosing to commence in NC i - MSC Œ pilot study” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Perform
- Deliverable
- i-MSC pilot study
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Citius Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-CTXR-023864 · Corrections policy